Melanoma screening by physicians associated with finding more cancers than patient self-detection

July 18, 2011, JAMA and Archives Journals

Physician-based screening for melanoma is associated with higher rates of physician-detected melanoma and detection of thinner melanoma, according to a report published Online First today by Archives of Dermatology, one of the JAMA/Archives journals.

The disease-specific survival rate for advanced-stage is poor, so detecting the cancer in an earlier stage is the best means to ensure a favorable prognosis, according to background information in the article. Previous research has demonstrated that find most melanomas, and that those lesions tend to be thicker than physician-detected lesions. "Working on the premise that physician-based screening and patient self-screening are vital in the detection of early melanoma," explain the authors, "we compared melanoma characteristics in patients new to our practice vs. established patients in the pigmented lesions clinic (PLC) at Memorial Sloan-Kettering Cancer Center" (MSKCC) in New York City.

Ivanka Kovalyshyn, D.O., from MSKCC, and colleagues conducted a retrospective review of and logs from two MSKCC pigmented lesion specialists from January 1998 through December 2008. The institution's PLC serves patients at high risk for developing melanoma, so each patient visit involves a total body skin examination, and patients are given brochures instructing them how to perform skin self-examination (SSE). Researchers divided the group into "established" patients, who had been treated at MSKCC's PLC for three months or more, and "new" patients who were new to the practice.

A total of 527 melanomas were identified in 394 patients. Among the established group, lesions tended to be thinner, more often detected in the in situ phase and less likely to exhibit negative prognostic attributes. Physicians detected 82 percent of melanomas in established patients and 63 percent in new patients. The overall patient-detection rate was 18 percent, and most found by patients were detected because of change in appearance.

"Although we recognized that patients may have more frequent physician skin examinations and may be more vigilant in performing SSE, we strongly believe that the PLC setting contributes to earlier detection of melanoma in our cohort," the authors write. They do note that the patient's role in melanoma recognition is important as well. "Therefore," they conclude, "it is crucial to emphasize that a combined strategy of physician detection and patient participation must continue to be implemented to ensure early melanoma diagnosis."

More information: Arch Dermatol. Published July 18, 2011. doi:10.1001/archdermatol.2011.181

Related Stories

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jul 19, 2011
The FDA has provided new guidelines regulating sunscreen. It took 33 years but the FDA released the previously proposed and rejected 2007 Sunscreen Safety Regulations Draft.

Talk about efficiency!

The draft itself says FDA is not aware of data demonstrating that sunscreen use alone helps prevent skin cancer (FDA 2007). Even worse, that there is reason to believe that sunscreen has the potential to increase the risk of melanoma.

Can you believe it? Thats why consulting a physician has never been more important. Some quick facts from reveal that:

One or more blistering sunburns in childhood or adolescence more than double a persons chances of developing melanoma later in life.
A persons risk for melanoma doubles if he or she has had more than five sunburns at any age.

To quote an article from Medscape:
The number of melanoma cases worldwide is increasing faster than any other cancer. The annual increase in incidence rate varies between populations, but i

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.